Ginkgo Bioworks Holdings Valuation
Is DNA * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of DNA * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate DNA *'s fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate DNA *'s fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for DNA *?
Key metric: As DNA * is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is DNA *'s PS Ratio? | |
|---|---|
| PS Ratio | 2.1x |
| Sales | US$217.95m |
| Market Cap | US$461.81m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.3x |
| Enterprise Value/EBITDA | -0.6x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does DNA *'s PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.9x | ||
CYDSASA A Cydsa. de | 0.6x | 10.6% | Mex$9.0b |
ALPEK A ALPEK. de | 0.2x | 5.6% | Mex$28.9b |
ORBIA * Orbia Advance Corporation. de | 0.2x | 5.7% | Mex$34.7b |
MFRISCO A-1 Minera Frisco. de | 2.4x | n/a | Mex$22.3b |
DNA * Ginkgo Bioworks Holdings | 2.1x | 1.8% | Mex$461.8m |
Price-To-Sales vs Peers: DNA * is expensive based on its Price-To-Sales Ratio (2.1x) compared to the peer average (0.9x).
Price to Sales Ratio vs Industry
How does DNA *'s PS Ratio compare vs other companies in the South American Chemicals Industry?
| 2 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 2 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: DNA * is expensive based on its Price-To-Sales Ratio (2.1x) compared to the Global Chemicals industry average (1.4x).
Price to Sales Ratio vs Fair Ratio
What is DNA *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 2.1x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate DNA *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | Mex$164.00 | Mex$167.74 +2.3% | 19.5% | Mex$204.56 | Mex$122.74 | n/a | 5 |
| Nov ’25 | n/a | Mex$176.14 0% | 16.7% | Mex$200.16 | Mex$140.11 | n/a | 5 |
| Oct ’25 | n/a | Mex$287.16 0% | 85.6% | Mex$776.11 | Mex$135.82 | n/a | 5 |
| Sep ’25 | Mex$76.25 | Mex$702.03 +820.7% | 118.0% | Mex$2,289.22 | Mex$133.54 | n/a | 5 |
| Aug ’25 | n/a | Mex$869.48 0% | 93.6% | Mex$2,158.70 | Mex$143.91 | n/a | 6 |
| Jul ’25 | n/a | Mex$1,015.54 0% | 72.8% | Mex$2,202.37 | Mex$146.82 | n/a | 6 |
| Jun ’25 | n/a | Mex$956.72 0% | 66.5% | Mex$2,002.43 | Mex$333.74 | n/a | 6 |
| May ’25 | n/a | Mex$1,303.70 0% | 40.5% | Mex$2,037.04 | Mex$679.01 | n/a | 5 |
| Apr ’25 | n/a | Mex$1,335.73 0% | 36.7% | Mex$2,034.11 | Mex$745.84 | n/a | 5 |
| Mar ’25 | n/a | Mex$1,477.21 0% | 38.4% | Mex$2,042.23 | Mex$748.82 | n/a | 5 |
| Feb ’25 | Mex$840.00 | Mex$2,118.46 +152.2% | 62.4% | Mex$4,809.48 | Mex$755.77 | n/a | 6 |
| Jan ’25 | Mex$1,199.60 | Mex$2,369.11 +97.5% | 58.8% | Mex$4,818.52 | Mex$860.45 | n/a | 6 |
| Dec ’24 | n/a | Mex$2,344.97 0% | 55.6% | Mex$4,858.50 | Mex$867.59 | n/a | 7 |
| Nov ’24 | n/a | Mex$2,694.15 0% | 80.0% | Mex$8,044.75 | Mex$838.00 | n/a | 8 |
| Oct ’24 | n/a | Mex$2,694.15 0% | 80.0% | Mex$8,044.75 | Mex$838.00 | n/a | 8 |
| Sep ’24 | n/a | Mex$2,694.15 0% | 80.0% | Mex$8,044.75 | Mex$838.00 | Mex$76.25 | 8 |
| Aug ’24 | Mex$1,575.60 | Mex$2,974.74 +88.8% | 75.5% | Mex$8,424.05 | Mex$877.51 | n/a | 8 |
| Jul ’24 | n/a | Mex$2,974.74 0% | 75.5% | Mex$8,424.05 | Mex$877.51 | n/a | 8 |
| Jun ’24 | n/a | Mex$3,133.17 0% | 68.3% | Mex$8,437.15 | Mex$1,230.42 | n/a | 8 |
| May ’24 | Mex$885.20 | Mex$3,286.92 +271.3% | 66.5% | Mex$8,728.75 | Mex$1,272.94 | n/a | 8 |
| Apr ’24 | n/a | Mex$3,335.51 0% | 63.7% | Mex$8,619.36 | Mex$1,256.99 | n/a | 8 |
| Mar ’24 | n/a | Mex$3,719.69 0% | 59.0% | Mex$9,063.22 | Mex$1,510.54 | n/a | 8 |
| Feb ’24 | Mex$1,800.00 | Mex$3,719.69 +106.6% | 59.0% | Mex$9,063.22 | Mex$1,510.54 | Mex$840.00 | 8 |
| Jan ’24 | n/a | Mex$4,000.67 0% | 55.4% | Mex$9,506.54 | Mex$2,376.64 | Mex$1,199.60 | 8 |
| Dec ’23 | n/a | Mex$4,475.20 0% | 54.5% | Mex$9,232.51 | Mex$2,308.13 | n/a | 9 |
| Nov ’23 | Mex$2,040.00 | Mex$6,070.97 +197.6% | 52.2% | Mex$11,573.26 | Mex$2,394.47 | n/a | 8 |
Analyst Forecast: Target price is lower than the current share price.
Discover undervalued companies
Celanese
US$8.0b
A chemical and specialty materials company, manufactures and sells high performance engineered polymers in the United States and internationally.
CE *
US$1,515.00
7D
1.3%
1Y
n/a
Companhia Siderúrgica Nacional
R$14.8b
Operates as an integrated steel producer in Brazil and Latin America.
SID N
R$37.95
7D
0%
1Y
-32.2%
Fortescue
AU$58.4b
Engages in the exploration, development, production, processing, and sale of iron ore in Australia, China, and internationally.
FMG1 N
AU$273.31
7D
0%
1Y
n/a